DavidScottIIIMD

Nephrology • Laurelton, NY

Medical Director/Principal Investigator; Institute for Clinical Studies

Join to view full profile

Dr. Scott is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Scott's full profile

Already have an account?

Office
23201 Merrick Blvd
Laurelton, NY 11413
Phone+1 718-276-4750

Fax+1 718-276-4751
Is this information wrong?

Education & Training

Harlem Hospital CenterFellowship, Nephrology, 1988 - 1990
Harlem Hospital CenterResidency, Internal Medicine, 1985 - 1988
Tufts University School of MedicineClass of 1985
Howard UniversityBS, 1976 - 1980

Certifications & Licensure

NY State Medical License 1988 - 2025
American Board of Internal Medicine Nephrology

Awards, Honors, & Recognition

Top Physician U.S. News & World Report, 2012
CMS Meaningful Use Stage 1 Certification Practice Fusion EHR, Practice Fusion, Inc., 2012-2013
Consumers' Research Council of America America's Top Physicians, 2010
Top Doctor New York & New Jersey Network Journal, 2010
Super Doctors New York Times, 2009
Everyday Heroes Award Kiwanis Club, 2009
Top Doctor: New Metro Area Castle-Connolly, 2009
Top African-American Nephrologist in New York Network Journal, 2007
Best Doctor New York City Better Living Magazine, 2005
Outstanding Achievement Through Fundraising and Volunteer Leadership Support 2004
Top Doctors Castle Connolly, 2003-2005, 2007, 2010-2014
Top Doctor New York Metro Area Castle Connolly Guide, 2003, 2006, 2011
Strathmore WHO's WHO in Nephrology 2003
Teaching Attending Award for Excellence in Teaching Catholic Medical Center, 1995
Join now to see all

Clinical Trials

E.V.O.L.V.E. Trial™: EValuation Of Cinacalcet Hydrochloride (HCl) Therapy to Lower CardioVascular Events Start of enrollment: 2006 Aug 22
Completed
Phase 3
Long Term Treatment of End Stage Renal Disease Patients With Lanthanum Carbonate (Fosrenol) Start of enrollment: 2006 Apr 25
Completed
Phase IIa Trial to Determine the Effects of Bardoxolone Methyl on Renal Function in Patients With Diabetic Nephropathy Start of enrollment: 2008 Apr 30
Completed
Phase 2
Phase III Study to Investigate the Safety and Efficacy of Fermagate and Sevelamer Hydrochloride Start of enrollment: 2009 Jul 01
Terminated
Phase 3
A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Tolerability of Oral Lixivaptan Capsules in Subjects With Euvolemic Hyponatremia Start of enrollment: 2009 Jun 01
Completed
Phase 3
Safety, Tolerability and Pharmacokinetics of Etelcalcetide in Hemodialysis Patients With Secondary Hyperparathyroidism Start of enrollment: 2010 Sep 07
Completed
Phase 1
Safety, Tolerability and Efficacy of Etelcalcetide in Hemodialysis Patients With Secondary Hyperparathyroidism Start of enrollment: 2011 Feb 20
Completed
Phase 2
Etelcalcetide to Treat Secondary Hyperparathyroidism in Hemodialysis Patients With Chronic Kidney Disease-Mineral and Bone Disorder Start of enrollment: 2011 Dec 05
Completed
Phase 2
A Phase 2 Study to Evaluate the Safety and Efficacy of CTP-499 in Type 2 Diabetic Nephropathy Patients Start of enrollment: 2012 Jan 01
Completed
Phase 2
Safety Study of Anti-Macrophage Migration Inhibitory Factor (Anti-MIF) Antibody in Lupus Nephritis Start of enrollment: 2011 Nov 28
Terminated
Phase 1
Safety and Efficacy of Combination Saxagliptin & Dapagliflozin Added to Metformin to Treat Subjects With Type 2 Diabetes Start of enrollment: 2012 Jul 01
Completed
Phase 3
A Study Comparing Dulaglutide With Insulin Glargine on Glycemic Control in Participants With Type 2 Diabetes (T2D) and Moderate or Severe Chronic Kidney Disease (CKD) Start of enrollment: 2012 Jul 01
Completed
Phase 3
A Study of Fresolimumab in Patients With Steroid-Resistant Primary Focal Segmental Glomerulosclerosis (FSGS) Start of enrollment: 2012 Aug 01
Completed
Phase 2
Phase 3 Study Evaluating Efficacy and Safety of DSC127 Compared With Vehicle and With Standard-of-care in Diabetic Foot Ulcers Start of enrollment: 2013 Apr 01
Terminated
Phase 3
Join now to see all

Publications & Presentations

PubMed

3 citations
Managing Chronic Kidney Disease in Type 2 Diabetes in Family Practice
David M. Scott, Jaime A. Davidson> ;Journal of the National Medical Association. 2011 Sep 1
Mild renal impairment and the efficacy and safety of liraglutide.
Davidson JA Brett J Falahati A Scott D> ;Endocr Pract. 2011 May-Jun
A 1-year randomized trial of calcium acetate versus sevelamer on progression of coronary artery calcification in hemodialysis patients with comparable lipid control: t...
Qunibi W Moustafa M Muenz LR He DY Kessler PD Diaz-Buxo JA Budoff M> ;Am J Kidney Dis. 2008 Jun

Journal Articles

The Treatment of Type 2 Diabetes in Chronic Kidney Disease: A Case for Linagliptin for the Treatment of Diabetes in Severe Renal Impairment
David Scott, MD, Endocrine Practice, 1/1/2013
Diagnosing and Treating Chronic Kidney Disease in Patients with Type 2 Diabetes in Family Practice
David Scott, MD, Jaime A. Davidson, MD, Journal of Diabetes and Its Complications, 1/1/2011
Reductions in HBA1c and the Incidence of Hypoglycemic Episodes Are Not Adversely Affected by Renal Impairment in Patients with Type 2 Diabetes Treated with Liraglutide
Gough S, Feldt-Rasmussen B, Davidson, Furber S, Donsmark M, Scott D, IDF, 1/1/2011
Managing Chronic Kidney Disease in Type 2 Diabetes in Family Practice
David Scott, MD; Jaime A. Davidson, MD, J National Medical Association, 1/1/2011
Mild Renal Impairment Has No Effect on the Efficacy and Safety of Liraglutide
David Scott, MD, Jaime A. Davidson, MD, Jason Brett, MD, Endocrine Practice, 1/1/2010
Baseline Characteristics in the Trial to Reduce Cardiovascular Events With Aranesp Therapy
Marc A. Pfeffer, MD., PhD, TREAT Investigators, AJKD, 1/1/2009
A 1-Year Randomized Trial of Calcium Acetate Versus Sevelemer on Progression of Coronary Artery Calcification in Hemodialysis Patients With Comparable Lipid Control: ...
Wajrh Quinabe, et.al. CARE-2 Investigators, AJKD, 1/1/2008
Correction of Anemia with Epoetin Alfa in Chronic Kidney Disease
Ajay K. Singh, CHOIR Investigators, NEJM, 1/1/2006
Coronary Artery Calcification in Hemodialysis Patients: Preliminary Results From the Calcium Acetate Renagel Evaluation -2 (CARE-2) Study
Wajeh Qunibi MD, Moustafa Moustafa MD, Paul Kessler MD, Larry Muenz PhD, Enoch Bortey PhD, Mathew Budoff MD and the CARE-2 Investigators, Scientific Session; American Society of Nephrology, 1/1/2006
Darbepoetin alfa Effectively Treats Anemia in Patients with Chronic Kidney Disease with DeNovo Every Other Week Administration
Scott, D., NESP Investigators, American J. Kidney Diseases, 1/21/2003
Major Outcomes in High-Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker vs Diuretic
Scott, D., ALLHAT Investigators, JAMA, 1/18/2002
Major Cardiovascular Events in Hypertensive Patients Randomized to Doxazosin vs Chlorthalidone
Scott, D., ALLHAT Investigators, JAMA, 1/19/2000
Extended Epoetin Alfa Dosing as Maintenance Treatment for the Anemia of Chronic Kidney Disease: The PROMPT Study
PROMPT Study Group, Clinical Nephrology
The Treatment of Type 2 Diabetes in Chronic Kidney Disease: A Case for Linagliptin for the Treatment of Diabetes in Severe Renal Impairment
David Scott, MD, Journal: Diabetes, Metabolic Syndrome and Obesity; Targets and Therapy
Efficacy and Safety of Liraglutide vs Placeba as Add-On to Existing Diabetes Medication in Subjects with Type 2 Diabetes and Moderate Renal Impairment
Phuong Ngo, Melanie Davis, Stephen Atkin, Stephen Bain, Peter Rossing, David Scott, et. al., LIRA-RENAL
Join now to see all

Abstracts/Posters

Efficacy and safety of liraglutide versus placebo by age subgroup in subjects with type 2 diabetes and moderate renal impairment (LIRA-RENAL): a randomized trial
Scott, D; Guillermo U; Atkin, S; Bain, S; Rossing, P; Shamkhalova, M; Bosch-Traberg, H; Syren, a; Davies, M, American Society of Nephrology, Philadelphia, Pa., 11/14/2014
Efficacy and safety of liraglutide vs placebo by eGFR subgroup in subjects with type 2 diabetes and moderate renal impairment (LIRA-RENAL): A randomized trial
Scott, D; et. al., American Society of Nephrology, Philadelphia, Pa., 11/14/2014
Efficacy and Safety of Liraglutide versus Placebo as Add-on to Existing Diabetes Medication in Subjects with Type 2 Diabetes and Moderate Renal Impairment (LIRA-RENAL).
Scott D, ADA, 1/1/2014
Efficacy and Safety of Liraglutide vs. Placebo by EGFR Subgroup in Subjects with Type 2 Diabetes and Moderate Renal Impairment (LIRA-RENAL): A Randomized Trial
Scott D, American Society of Nephrology, Philadelphia, 1/1/2014
In Patients with Type 2 Diabetes Treated with Liraglutide, Reductions in HbA1c and the Incidence of Hypoglycemic Episodes Are Not Affected by Renal Impairment
Scott D, Diabetes UK, 1/1/2012
Renal Impairment Does Not Affect the Glycemic Efficacy or Safety of Liraglutide Treatment in Patients with Type 2 Diabetes
Scott D, International Diabetes Federation, 1/1/2011
Reductions in HbA1c, and the Incidence of Hypoglycemic Episodes Are Not Adversely Affected by Renal Impairment in Patients with Type 2 Diabetes Treated with Liraglutide
Scott D, EASD, 1/1/2011
Join now to see all